MN SF4521

Changes commissioner's authority from permissive ("may") to mandatory ("shall") for providing separate reimbursement to hospitals for biological products used in cell or gene therapy to treat rare diseases in inpatient settings

Removes the previously required July 1, 2025 effective date and eliminates the condition requiring federal approval of documentation for value-based arrangements

Eliminates the requirement that drug manufacturers enter into a value-based arrangement with the commissioner before hospitals can receive separate reimbursement

Removes the prescribed methodology for establishing reimbursement rates that was based on outpatient drug administration rates

Requires hospitals to be paid actual acquisition cost for qualifying biological products used to treat rare diseases as defined in federal law (21 U.S.C. § 360bb)